BerGenBio posts updated data on trial of elderly AML patients

BerGenBio has posted updated data from its phase 2 trial of bemcentinib in acute myeloid leukaemia (AML). The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.